Exploratory study of ovarian intraepithelial neoplasia

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 2, 2005, Pages 299-305

  Brewer, Molly A ^a,c   Ranger Moore, James ^b   Baruche, Amy ^a   Alberts, David S ^a   Greene, Mark ^b   Thompson, Deborah ^b   Liu, Yun ^c   Davis, John ^a   Bartels, Peter H ^b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ALGORITHM; ARTICLE; CANCER PREVENTION; CANCER RISK; CARCINOMA IN SITU; CELL NUCLEUS; CELL ULTRASTRUCTURE; CHROMATIN STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; DISCRIMINANT ANALYSIS; EARLY DIAGNOSIS; EPITHELIUM; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; KARYOMETRY; OVARY CANCER; PHENOTYPE; PRECANCER; PRIORITY JOURNAL; PROGNOSIS; TISSUE SECTION;

CARCINOMA IN SITU; CELL NUCLEUS; CHROMATIN; EPITHELIAL CELLS; EPITHELIUM; FEMALE; HUMANS; KARYOMETRY; OVARIAN NEOPLASMS; OVARY; PRECANCEROUS CONDITIONS; RISK;

EID: 13944276354     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-04-0212     Document Type: Article

References (24)

1. Greene MH, Clark JW, Blayney DW. The epidemiology of ovarian cancer. Semi Oncol 1984;11:209-26.
2. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA-1 mutation carriers. Am J Hum Genet 1995;56:265-71.
3. Deligdisch L, Miranda C, Barba J, Gil J. Ovarian dysplasia: nuclear texture analysis. Cancer 1993;72:325-57.
4. Deligdisch L, Gil J, Kerner K, Wu HS, Beck D, Gershoni-Baruch R. Ovarian dysplasia in prophylactic oophorectomy specimens, cytogenetic and morphometric correlations. Cancer 1999;86:1544-50.
5. Salazar H, Godwin AK, Daly MB, et al. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 1996;88:1810-20.
6. Lu K, Garber J, Cramer D, et al. Occult ovarian tumors in women with BRCA-1 or BRCA-2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 2000;18:2728-32.
7. Puls L, Powell D, DePriest PD, et al. Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. Gynecol Oncol 1992;47:53-7.
8. Stratton JF, Buckley CH, Lowe D, Ponder BAJ; UKCCCR Familial Ovarian Cancer Study Group. Comparison of prophylactic oophorectomy specimens from carriers and non-carriers of a BRCA-1 or BRCA-2 gene mutation. J Natl Cancer Inst 1999;91:626-8.
9. Barakat RR, Federici MG, Saigo PE, Robson ME, Offit K, Boyd J. Absence of premalignant histologic, molecular or cell biologic alterations in prophylactic oophorectomy specimens from BRCA-1 heterozygotes. Cancer 2000; 89:383-90.
10. Narod SA, Dube MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P. Oral contraceptives and the risk of breast cancer in BRCA-1 and BRCA-2 mutation carriers. J Natl Cancer Inst 2002;94:1773-9.
11. Bartels PH, Montironi R, Hamilton PW, Thompson D, Vaught L, Bartels HG. Nuclear chromatin texture in prostatic lesions. II. PIN and malignancy associated changes. Anal Quant Cytol Histol 1998;20:397-406.
12. Anderson N, Houston J, Kirk SJ, et al. Malignancy associated changes in lactiferous duct epithelium. Anal Quant Cytol Histol 2003;25:63-72.
13. Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history [see comment]. J Nat Cancer Inst 1997;89:227-38.
14. Young T, Verbeek, PW, Mayall B. Characterization of chromatin distributions in cell nuclei. Biometry 1968;7:467-74.
15. Galoway M. Texture analysis using gray level run lengths. Computer Graphs and Image Processing 1975;4:172.
16. Bartels PH, da Silva VD, Montironi R, et al. Chromatin texture signatures in nuclei from prostate lesions. Anal Quant Cytol Histol 1998;20:407-16.
17. Weyn B, Jacob W, da Silva VD, et al. Data representation and reduction for chromatin texture in nuclei from premalignant prostatic, esophageal and colonic lesions. Cytometry 2000;41:133-8.
18. Wied GL, Bartels PH, Bahr GF, Oldfield DG. Taxonomic intracellular analytic system (TICAS) for cell identification. Acta Cytol 1968;12:180-204.
19. Beal EMI. Euclidean cluster analysis. Bull Intl Stat Inst 1969;43:21-43.
20. Montironi R, Scarpelli M, Mazzucchelli R, et al. Sub-visual chromatin changes are detected in the histologically normal urothelium in patients with synchronous papillary carcinoma. Hum Pathol 2003;34:893-901.
21. Wied GL, Bartels PH, Bibbo M, Sychra JJ. Cytomorphometric markers for uterine cancer in intermediate cells. Anal Quant Cytol Histol 1980;2:257-63.
22. Susnik B, Worth A, LeRiche J, Palcic G. Malignancy associated changes in the breast. Changes in chromatin distribution in epithelial cells in normal appearing tissue adjacent to cancer. Anal Quant Cytol Histol 1995;17:62-8.
23. Montag AG, Bartels PH, Dytch HE, Lerma-Puertas E, Michelassi F, Bibbo M. Karyometric features in nuclei near colonic adenocarcinoma. Statistical analysis. Anal Quant Cytol Histol 1991;13:159-67.
24. Bibbo M, Bartels PH, Galera-Davidson H, Dytch HE, Wied GL. Markers for malignancy in the nuclear texture of histologically normal tissue from patients with thyroid tumors. Anal Quant Cytol Histol 1986;8:168-76.